Sunitinib prior to planned cytoreductive nephrectomy: Is this the new litmus test for metastatic renal cell carcinoma?

European Urology

Volumn 60, Issue 3, 2011, Pages 455-456

  Kim, Simon P ^a   Thompson, R Houston ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; IMMUNOLOGIC AGENT; SUNITINIB;

CLINICAL TRIAL (TOPIC); CYTOREDUCTIVE SURGERY; DRUG EFFICACY; EDITORIAL; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; NEPHRECTOMY; PROTEIN KINASE INHIBITORS; PYRROLES;

EID: 79960974237     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.05.056     Document Type: Editorial

References (10)

1. Flanigan RC, Yonover PM. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Urol Oncol 2001;19:98-102. (Pubitemid 32410342)
2. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-6.
3. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-70. (Pubitemid 32913522)
4. Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: kidney cancer. 2011. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician-gls/pdf/kidney.pdf. Accessed May 1, 2011
5. Powles T, Blank C, Chowdhury S, et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur Urol 2011;60:448-54.
6. Powles T, Kayani I, Blank C, et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol 2011;22:1041-7.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356: 115-24. (Pubitemid 46089672)
9. European Organization for Research and Treatment of Cancer. Immediate surgery or surgery after sunitinb malate in patients with metasatic kidney cancer [identifier NCT01099423]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/results?term=NCT01099423. Accessed May 1, 2011.
10. Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011;185:60-6.